论文部分内容阅读
目的：观察蝮蛇抗栓酶与扩血管药合用治疗突发性聋的临床疗效．方法：８９例患者用大剂量蝮蛇抗栓酶与扩血管药合用为治疗组．对照组１１３例仅用扩血管药治疗．结果：治疗组的痊愈率为３６．６％，有效率为７６．２％；对照组痊愈率为２９．３％，有效率为６９．９％．两组比较无显著差异（Ｐ＞０．０５），但治疗组治疗前病程（平均４１．６ｄ）较对照组（平均１０．６ｄ）长．结论：大剂量蝮蛇抗栓酶与扩血管药联合治疗突聋疗效肯定，尤其对病程较长突聋患者的治疗提供一可供选择的有效疗法．
Objective: To observe the clinical efficacy of combination of viper antithrombin and vasodilator in the treatment of sudden deafness. Methods: 89 patients were treated with high-dose viper snake antithrombin and vasodilator for the treatment group. The control group of 113 cases only vasodilator treatment. Results: The cure rate in the treatment group was 36.6%, the effective rate was 76.2%. The cure rate in the control group was 29.3% and the effective rate was 69.9%. There was no significant difference between the two groups (P> 0.05), but the treatment group before treatment (average 41.6d) than the control group (average 10.6d) longer. Conclusion: The combination of high-dose viper snake antithrombin and vasodilator drug has definite effect on sudden deafness, especially for the treatment of patients with longer course deafness.